A Pharmacokinetic Study of PEG-Intron [peginterferon alfa-2b], Administered Weekly in Subjects With High-Risk Melanoma.

Trial Profile

A Pharmacokinetic Study of PEG-Intron [peginterferon alfa-2b], Administered Weekly in Subjects With High-Risk Melanoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 27 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2012 Companies (Merck and Co, Merck Sharp and Dohme) added as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Trial phase changed from I to II/III as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top